Nestle is developing new products designed to meet the nutritional needs of users of weight-loss medications, the company’s executives said on Monday.
The Swiss food and beverage conglomerate is responding to growing demand for GLP-1 receptor agonist drugs such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, which have driven significant shifts in consumer eating habits. These medications, originally developed for diabetes, suppress appetite and slow digestion, often leading to reduced calorie intake and altered food preferences.
Nestle’s chief executive, Mark Schneider, told investors that the company is exploring formulations that align with the dietary requirements of weight-loss drug users. While specifics were limited, Schneider indicated that the new products would focus on high-protein, low-calorie options, as well as fortified foods to address potential nutrient deficiencies associated with reduced food consumption.
The strategy reflects broader industry trends, as food manufacturers adapt to the rise of prescription weight-loss treatments. Nestle joins peers such as PepsiCo and General Mills in evaluating how to serve this expanding consumer segment, which has seen rapid adoption in recent years.
Analysts note that the shift could open new revenue streams for food companies, though challenges remain in balancing taste, convenience, and nutritional value. The market for GLP-1 drugs is projected to exceed $100 billion by 2030, according to industry estimates, underscoring the commercial potential for tailored food products.
Nestle declined to provide a timeline for the launch of these products or disclose financial projections related to the initiative.
